Tuberculosis Infected AIDS Patients Benefiting from Administration of ACE Water

    SOUTH PASADENA, CA, October 25, 2015 /24-7PressRelease/ -- As reported in a recently published study from Ukraine, nine severely ill AIDS patients agreed to a 4-months delay in beginning anti-retroviral drug therapy. During this time, the patients received activated water to bolster their alternative cellular energy (ACE) pathway, along with regular anti-tuberculosis (TB) medications. The ACE Water was provided by injection and inhalation.

This non-toxic therapy led to greater than 60% reduction in the virus load levels of HIV; increases in CD4 lymphocyte counts and markedly improved quality of life. The patients also became sputum negative for TB by the second month of treatment. Seven of eight individuals who were initially evaluated for the ACE Water trial but instead received anti-retroviral therapy died during the study and the surviving patient was sputum positive for TB. The failure of anti-retroviral therapy in the control patients is a reflection the severity of the illness in the ACE Water treated patients. The ACE pathway is a dynamic (kinetic) quality of the body's fluids, resulting from loosening of the intermolecular hydrogen bonding between water molecules.

An external force termed KELEA (kinetic energy limiting electrostatic attraction) reduces the strength of hydrogen bonding allowing for improved biological activities. The ACE pathway is an adjunct to cellular energy derived from the metabolism of food with additional properties related to enhanced cognitive brain function and defenses against infections. Given that HIV severely damages the immune system, it places a greater emphasis on enhancing the non-immunological defenses supported by the ACE pathway.

The AIDS study was mentioned at the recent meeting of the AIDS Commission of Los Angeles as providing a strong incentive to expand clinical trials of ACE Water in the prevention and therapy of HIV and associated illnesses.

Copies of the reported peer-reviewed study from the "Journal of Human Virology and Retrovirology" are available at http://medcraveonline.com/JHVRV/JHVRV-02-00061.pdf

About Institute of Progressive Medicine
Further inquiries on the ACE Pathway can be directed to Dr. W. John Martin, Medical Director of the Institute of Progressive Medicine, a component of MI Hope Inc., a non-profit public charity. His can be reached by e-mail at [email protected]

# # #